Hans H Hirsch

Universität Basel, Bâle, Basel-City, Switzerland

Are you Hans H Hirsch?

Claim your profile

Publications (194)1011.54 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: JC polyomavirus (JCPyV) can cause progressive multifocal leukoencephalopathy (PML), a debilitating, often fatal brain disease in immunocompromised patients. JCPyV-seropositive multiple sclerosis (MS) patients treated with natalizumab have a 2- to 10-fold increased risk of developing PML. Therefore, JCPyV serology has been recommended for PML risk stratification. However, different antibody tests may not be equivalent. To study intra- and inter-laboratory variability, sera from 398 healthy blood donors were compared in 4 independent enzyme-linked immunoassay (ELISA) measurements generating >1592 data points. Three datasets (Basel1, Basel2, Basel3) used the same basic protocol, but different JCPyV virus-like particle (VLP) preparations and introduced normalization to a reference serum. The datasets were also compared with an independent method using biotinylated VLPs (Helsinki1). VLP preadsorption reducing ≥35% activity was used to identify seropositive sera. The results indicated that Basel1, Basel2, Basel3, and Helsinki1 were similar regarding overall data distribution (P=0.79) and seroprevalence (58.0%, 54.5%, 54.8%, 53.5%, respectively; P=0.95). However, intra-assay intra-laboratory comparison yielded 3.7% to 12% discordant results, most of which were close to the cut-off (0.080<OD<0.250) according to Bland-Altman analysis. Introducing normalization improved overall performance and reduced discordance. The inter-laboratory inter-assay comparison between Basel3 and Helsinki1 revealed only 15 discordant results, of which 14 (93%) were close to cut-off. Preadsorption identified specificities of 99.44% and 97.78% and sensitivities of 99.54% and 95.87% for Basel3 and Helsinki, respectively. Thus, normalization to a preferably WHO-approved reference serum, duplicate testing and preadsorption for samples around the cut-off may be necessary for reliable JCPyV-serology and PML risk stratification.
    Clinical and vaccine Immunology: CVI 09/2014; · 2.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To the Editor: Boulware et al. (June 26 issue)(1) address the timing of initiation of antiretroviral therapy (ART) for human immunodeficiency virus-associated cryptococcal meningitis, and they conclude that excess mortality in association with "earlier ART" was probably due to the immune reconstitution inflammatory syndrome (IRIS). However, they reported no significant difference in the incidence of IRIS between the two groups (P=0.32). Another explanation could be that more participants had elevated intracranial pressure at diagnosis in the earlier-ART group than in the deferred-ART group (58% vs. 51%). If the 24 participants in whom intracranial pressure was not measured at diagnosis are . . .
    New England Journal of Medicine 09/2014; 371(12):1165-1167. · 54.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The presence of minority nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 variants prior to antiretroviral therapy (ART) has been linked to virologic failure in treatment-naive patients.
    AIDS (London, England) 07/2014; · 4.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gastrointestinal infections are caused by a broad spectrum of pathogens. Conventional diagnostic procedures are resource and time consuming due to single pathogen testing, often in different laboratories.
    Infection 07/2014; · 2.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Previous studies have associated activating Killer cell Immunoglobulin-like Receptor (KIR) genes with protection from cytomegalovirus (CMV) replication after organ transplantation. Whether KIR-associated protection is operating in the context of primary infection, re-activation, or both, remains unknown. Here we correlated KIR genotype and CMV serostatus at the time of transplantation with rates of CMV viremia in 517 heart (n=57), kidney (n=223), liver (n=165) or lung (n=72) allograft recipients reported to the Swiss Transplant Cohort Study. Across the entire cohort we found B haplotypes-which in contrast to A haplotypes may contain multiple activating KIR genes-to be protective in the most immunosuppressed patients (receiving anti-thymocyte globulin induction and intensive maintenance immunosuppression) (hazard ratio after adjustment for covariates 0.46, 95% confidence interval 0.29-0.75, P=0.002). Notably, a significant protection was detected only in recipients who were CMV-seropositive at the time of transplantation (HR 0.45, 95% CI 0.26-0.77, P=0.004), but not in CMV seronegative recipients (HR 0.59, 95% CI 0.22-1.53, P=0.28). These data indicate a prominent role for KIR-and presumably natural killer (NK) cells-in the control of CMV replication in CMV seropositive organ transplant recipients treated with intense immunosuppression.Genes and Immunity advance online publication, 10 July 2014; doi:10.1038/gene.2014.39.
    Genes and immunity. 07/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Rationale: Invasive fungal disease (IFD) is a significant cause of morbidity and mortality in immunocompromised patients. Objectives: We hypothesize that galactomannan, a component of fungal cell wall, as measured in the bronchoalveolar lavage (BAL-GM) might be a diagnostic adjunct in hematological malignancies. Methods: 568 hematological cases undergoing diagnostic bronchoscopy due to respiratory symptoms and/or suspected IFD between 2009 and 2013 at a tertiary care center in Switzerland were included in this prospective, observational cohort study. We compared accuracy of the BAL-GM ELISA determination in predicting IFD as classified by the EORTC/MSG definition. Measurements and Main Results: BAL-GM was positive in 155 cases (29.2%). According to the EORTC/MSG criteria, IFD was classified as possible in 182 (34.3%), probable in 45 (8.5%) and proven 6 (1.1%). BAL-GM provided 50% sensitivity, 73.0% specificity, 16% PPV, and 93% NPV for diagnosing proven+probable IFD. Results were similar when antifungal treatment and radiologic suspicion of IFD were used as the gold standard. The AUC of the ROC curve (AUC) for the diagnosis of proven+probable IFD was 0.716 (95%CI 0.638-0.794, p<0.001). Conclusions: Galactomannan in the BAL had modest agreement with EORTC/MSG criteria for diagnosing invasive fungal disease in immunocompromised patients with a high degree of antifungal exposure.
    American Journal of Respiratory and Critical Care Medicine 07/2014; · 11.04 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: No reliable treatment options are known for progressive multifocal leukoencephalopathy with underlying immunodeficiency. We describe successful compassionate use of recombinant human interleukin 7 in a patient with idiopathic CD4+ T-cell lymphocytopenia.
    JAMA Neurology 06/2014; · 7.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The human fetal glial cell line SVG was generated in 1985 by transfecting primary fetal brain cells with a plasmid containing an origin-defective mutant of simian virus 40 (SV40). The cells, which express SV40 large T-antigen, support the replication of human JC polyomavirus (JCPyV) and have been used for JCPyV studies but also for other studies where cells of neural origin were desirable. We intended to use the SVG p12 cells from ATCC for antiviral drug studies with JCPyV. However, during initial experiments, immunofluorescence microscopy controls unexpectedly revealed cells expressing the late viral proteins VP1, VP2/VP3 and agno. This was confirmed by western blotting. Since the agnoprotein antiserum is specific for BKPyV-agnoprotein, infection with BKPyV was suspected. Indeed specific BKPyV PCR of SVG p12 supernatants revealed a viral load of >1×10(10) genomic equivalents/ml. Negative staining electron microscopy showed characteristic polyomavirus virions and infectious BKPyV was transmitted from SVG p12 supernatant to other cells. Long-range PCR covering the viral genome followed by DNA sequencing, identified BKPyV strain UT as well as deletion derivatives. This was confirmed by next generation sequencing. JCPyV (MAD-4) was found to infect apparently uninfected and BKPyV-infected SVG p12 cells. In total, 4 vials from 2 different ATCC lots of SVG p12 cells dating back to 2006 contained BKPyV, whereas the subclone SVG-A was negative. In conclusion, SVG p12 cells from ATCC contain infectious BKPyV. This may have affected results and interpretation of previous studies and caution should be taken in future experiments. This work reveals that one of the most frequently used cell lines for JC polyomavirus (JCPyV) research, the SV40-immortalized human fetal glial cell line SVG obtained directly from ATCC, contains infectious BK polyomavirus (BKPyV) of UT strain and a spectrum of defective mutants. The UT strain has been previously found in urine and in tumours of different patients but is also frequently used for research. It is therefore not clear if BKPyV was present in the brain tissue used to generate the cell line or if this is a contamination. Although a productive JCPyV of SVG cells was not dependent on prior BKPyV infection, the unknown BKPyV infecton may have influenced the results of studies performed in these cells. However, the frequently used subclone SVG-A did not contain BKPyV. The interpretation of past results should therefore be reconsidered and cells tested for BKPyV before new studies are initiated.
    Journal of Virology 04/2014; · 5.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: B-cells in airways and lung parenchyma may be involved in COPD evolution. However, whether their pathogenic role is beneficial or harmful remains controversial. The objective of this study was to investigate the maturation of adenovirus-specific immunoglobulins in COPD patients in respect to clinical outcome. The presence of adenovirus-specific immunoglobulins during acutely exacerbated COPD (AECOPD) was analyzed at exacerbation and 2-3 weeks later. Patients with detectable adenovirus-specific IgM and low IgG avidity were grouped into fast and delayed IgG maturation. The clinical outcome of both groups was evaluated. Out of 208 patients, 43 patients (20.7%) had serologic evidence of recent adenovirus infection and were grouped into 26 patients with fast IgG maturation and 17 patients with delayed IgG maturation. Baseline characteristics, AECOPD therapy, and duration of hospitalization were similar in both groups. However, the AECOPD recurrence rate within six months was higher (p = 0.003) and there was a trend for earlier AECOPD related re-hospitalizations (p = 0.061) in patients with delayed IgG maturation. The time to re-hospitalization or death within two years was shorter in patients with delayed IgG maturation (p = 0.003). Adenovirus-specific IgG maturation was an independent predictor of both, the number of recurrent AECOPDs within six months (p = 0.001) and the occurrence of hospitalization or death within two years (p = 0.005). Delayed immunoglobulin avidity maturation, following COPD exacerbation, is associated with worse outcome.
    Chest 04/2014; · 7.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BK polyomavirus (BKPyV) infection is widespread and typically asymptomatic during childhood, but may cause nephropathy in kidney transplant recipients. However, there is only limited knowledge on BKPyV-specific immunity in children and adults, and its role in BKPyV-replication and disease posttransplant. We therefore characterized BKPyV-specific immunity from 122 immunocompetent individuals (1–84 years), 38 adult kidney recipients with (n = 14) and without BKPyV-associated complications (n = 24), and 25 hemodialysis (HD) patients. Blood samples were stimulated with overlapping peptides of BKPyV large-T antigen and VP1 followed by flow-cytometric analysis of activated CD4 T cells expressing interferon-γ, IL-2 and tumor necrosis factor-α. Antibody-levels were determined using enzyme-linked immunosorbent assay. Both BKPyV-IgG levels and BKPyV-specific CD4 T cell frequencies were age-dependent (p = 0.0059) with maximum levels between 20 and 30 years (0.042%, interquartile range 0.05%). Transplant recipients showed a significantly higher BKPyV-specific T cell prevalence (57.9%) compared to age-matched controls (21.7%) or HD patients (28%, p = 0.017). Clinically relevant BKPyV-replication was associated with elevated frequencies of BKPyV-specific T cells (p = 0.0002), but decreased percentage of cells expressing multiple cytokines (p = 0.009). In conclusion, BKPyV-specific cellular immunity reflects phases of active BKPyV-replication either after primary infection in childhood or during reactivation after transplantation. Combined analysis of BKPyV-specific T cell functionality and viral loads may improve individual risk assessment.
    American Journal of Transplantation 04/2014; · 6.19 Impact Factor
  • Klinische Monatsblätter für Augenheilkunde 04/2014; 231(4):304-6. · 0.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We report on a 65-year-old male patient with a Shiga-toxin producing Escherichia coli O51:H49 gastrointestinal infection and sepsis associated with hemolytic uremic syndrome (HUS) with a fatal outcome. The strains isolated harbored stx2e and eae, a very unusual and new virulence profile for a HUS-associated enterohemorrhagic E. coli.
    Journal of clinical microbiology 02/2014; · 4.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cytomegalovirus (CMV) is the most frequent infectious complication following solid organ transplantation (SOT). The virus, in this population, is responsible for both direct (viral syndrome, hepatitis, pneumonitis, colitis…) and indirect effects (rejection, infections by other microorganisms and graft dysfunction). In this evidence-based guideline we dealt with the most important aspects of CMV infection in SOT recipients, including pre and post-transplant diagnosis assessment, risk factors with special emphasis in the prevention and treatment of this viral infection. Overall, an adequate management of CMV infection is a critical aspect in transplant patient care. This article is protected by copyright. All rights reserved.
    Clinical Microbiology and Infection 02/2014; · 4.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Community-acquired respiratory viruses (CARVs) are a frequent cause of disease in solid-organ transplant (SOT) recipients. Lower respiratory tract infections with CARV can be associated with significant morbidity and even mortality in this population. The impact of CARV infections on the progression of chronic allograft dysfunction in lung transplant recipients remains controversial. This article is protected by copyright. All rights reserved.
    Clinical Microbiology and Infection 02/2014; · 4.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human polyomaviruses (HPyVs) are a growing challenge in immunocompromized patients in view of the increasing number of now 12 HPyV species and their diverse disease potential. Currently, histological evidence of disease is available for BKPyV causing nephropathy and hemorrhagic cystitis, JCPyV causing progressive multifocal leukoencephalopathy and occasionally nephropathy, MCPyV causing Merkel cell carcinoma and TSPyV causing trichodysplasia spinulosa, two proliferative skin diseases. Here, the current role of HPyV in solid organ transplantation (SOT) was reviewed and recommendations regarding screening, monitoring and intervention were made. Pretransplant screening of SOT donor or recipient fro serostatus or active replication is currently not recommended for any HPyV. Posttransplant, however, regular clinical search for skin lesions including those associated with MCPyV or TSPyV is recommended in all SOT recipients. Also, regular screening for BKV replication e.g. by plasma viral load is recommended In kidney transplant recipients. For SOT patients with probable or proven HPyV disease, reducing immunosuppression should be considered to permit regaining of immune control. Antivirals would be desirable for treating proven HPyV disease, but are solely considered as adjunct local treatment of trichodysplasia spinulosa, whereas surgical resection and chemotherapy are key in Merkel cell carcinoma. Overall, the quality of the clinical evidence and the strength of most recommendations is presently limited, but is expected to be improving in the coming years. This article is protected by copyright. All rights reserved.
    Clinical Microbiology and Infection 01/2014; · 4.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Post-transplant lymphoproliferative disorder (PTLD) is a severe complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) associated with Epstein-Barr virus (EBV). Clinical presentations: Among 263 individuals treated with allo-HSCT for severe aplastic anemia, pure white cell aplasia, T-prolymphocytic leukemia, and relapsed Hodgkin lymphoma, we diagnosed EBV-PTLD in 5 patients. Median age was 29 years (range 19-70 years) and four of five patients were EBV-seropositive prior to HSCT. All five had unrelated EBV-positive donors. In all cases, PTLD occurred within the first year post-transplant (median 4 months). There were two rapidly fatal courses with extensive organ involvement. Both patients showed lymphopenia and thrombocytopenia. In contrast, the three surviving patients had higher lymphocytes and normal platelet counts, while PTLD was restricted to one site and resolved after 2-4 cycles of rituximab. In this case series courses of PTLD showed substantial diversity.
    Hematology (Amsterdam, Netherlands) 09/2013; · 1.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cytomegalovirus (CMV) replication in organ transplant recipients is commonly diagnosed by quantitative PCR methods. However, there has been a poor inter-laboratory correlation of viral load values due to the lack of an international reference standard. In a recent study, the COBAS® AmpliPrep/COBAS® TaqMan® (CAP/CTM) CMV test calibrated to the 1st WHO CMV standard, showed good reproducibility in CMV load values across multiple laboratories. Fifty-seven follow-up plasma specimens from 10 kidney transplant recipients with CMV replication were examined using the new quantitative CAP/CTM CMV test and the "in-house" quantitative CMV real-time PCR method, also calibrated against the 1st WHO CMV standard for their clinical applicability for monitoring CMV load in renal transplant patients. By CAP/CTM CMV test 49/57 specimens were CMV-DNA positive compared to 44/57 by the "in-house" PCR test. The "in-house" PCR and CAP/CTM CMV test correlated well in monitoring individual kidney transplant patients. Conversion of the CMV-DNA copies to IUs made the results of the "in-house" PCR and CAP/CTM CMV test less uniform in analysis of the patient samples. In specimens of one patient, significant underquantification of CMV load with "in-house" PCR emerged during follow-up due to a point mutation in the "in-house" PCR primer sequence. The CAP/CTM CMV test was found suitable for diagnosing and monitoring CMV replication in renal transplant patients. Multicenter studies are needed to provide more information of the commutability of the 1st WHO CMV standard and to define the clinical thresholds. J. Med. Virol. © 2013 Wiley Periodicals, Inc.
    Journal of Medical Virology 09/2013; · 2.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: JC (JCPyV) and BK polyomaviruses (BKPyV) infect 50-90% of the general population and thereafter persist with asymptomatic shedding. Previous studies have revealed a delayed antibody response to neo-antigens in children and adolescents who were thymectomized due to congenital heart defects. The present longitudinal study aimed at analyzing the seroprevalence and the antibody persistence against BKPyV and JCPyV in a 3-years time period in thymectomized patients (TP) compared to healthy controls (HC). Given the widespread primary and secondary exposure to BKPyV and JCPyV, we examined the impact of childhood thymectomy on specific IgG levels by ELISA using the respective virus-like particles. IgG-anti-BKPyV levels which were lower at beginning of the study increased in TP after a 3-years time interval and correlated with age. In contrast, IgG-anti-BKPyV levels decreased in HC within the same time period. Individuals losing humoral immunity against BKPyV and JCPyV were seen in both TP and HC. Although seroprevalence and maintenance of antibodies against BKPyV and JCPyV were similar between TP and HC, a more dynamic process was suggested for TP, with a probably delayed humoral immune response in some patients but similar waning of antibodies compared to HC. Our study supports the hypothesis that in thymectomy, similar to vaccination, antibody responses to neo-antigens are delayed. The assessment of long-term antibody stability together with cellular reactivity and detection of viremic episodes will elucidate further aspects of controlling of persistent viral infections in thymectomized individuals and the role of a complete thymus.
    Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 09/2013; · 3.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We assessed the impact of antiviral prophylaxis and preemptive therapy on the incidence and outcomes of cytomegalovirus (CMV) disease in a nationwide prospective cohort of solid organ transplant recipients. Risk factors associated with CMV disease and graft failure-free survival were analyzed using Cox regression models. One thousand two hundred thirty-nine patients transplanted from May 2008 until March 2011 were included; 466 (38%) patients received CMV prophylaxis and 522 (42%) patients were managed preemptively. Overall incidence of CMV disease was 6.05% and was linked to CMV serostatus (D+/R- vs. R+, hazard ratio [HR] 5.36 [95% CI 3.14-9.14], p < 0.001). No difference in the incidence of CMV disease was observed in patients receiving antiviral prophylaxis as compared to the preemptive approach (HR 1.16 [95% CI 0.63-2.17], p = 0.63). CMV disease was not associated with a lower graft failure-free survival (HR 1.27 [95% CI 0.64-2.53], p = 0.50). Nevertheless, patients followed by the preemptive approach had an inferior graft failure-free survival after a median of 1.05 years of follow-up (HR 1.63 [95% CI 1.01-2.64], p = 0.044). The incidence of CMV disease in this cohort was low and not influenced by the preventive strategy used. However, patients on CMV prophylaxis were more likely to be free from graft failure.
    American Journal of Transplantation 08/2013; · 6.19 Impact Factor
  • Source
    Virology. 07/2013; 441(2):197–199.

Publication Stats

6k Citations
1,011.54 Total Impact Points

Institutions

  • 1998–2014
    • Universität Basel
      • • Department of Biomedicine
      • • Institut für Medizinische Mikrobiologie
      • • Institut für Pathologie
      Bâle, Basel-City, Switzerland
  • 2013
    • University of Wuerzburg
      • Department of Paediatrics
      Würzburg, Bavaria, Germany
    • Helsinki University Central Hospital
      Helsinki, Southern Finland Province, Finland
    • Karolinska University Hospital
      Tukholma, Stockholm, Sweden
  • 2007–2013
    • University Hospital of North Norway
      • Department of Microbiology and Infection Control
      Tromsø, Troms Fylke, Norway
    • Dalhousie University
      Halifax, Nova Scotia, Canada
  • 1998–2013
    • Universitätsspital Basel
      • Klinik für Infektiologie & Spitalhygiene
      Bâle, Basel-City, Switzerland
  • 2012
    • Universität des Saarlandes
      • Institut für Virologie
      Homburg, Saarland, Germany
    • Hospital Universitario de La Princesa
      Madrid, Madrid, Spain
  • 2010
    • University of Helsinki
      Helsinki, Southern Finland Province, Finland
    • Haukeland University Hospital
      • Department of Neurology
      Bergen, Hordaland Fylke, Norway
    • National Institutes of Health
      Maryland, United States
  • 2009
    • City of Hope National Medical Center
      • Department of Virology
      Duarte, CA, United States
    • Universitetet i Tromsø
      Tromsø, Troms, Norway
  • 2004–2009
    • University of Maryland, Baltimore
      • • Division of Nephrology
      • • Department of Medicine
      • • Department of Pathology
      Baltimore, MD, United States
  • 2008
    • Swiss Tropical and Public Health Institute
      • Department of Epidemiology and Public Health
      Bâle, Basel-City, Switzerland
  • 2006
    • Royal Holloway, University of London
      • Department of Biological Sciences
      Egham, ENG, United Kingdom
    • Hospital of the University of Pennsylvania
      Philadelphia, Pennsylvania, United States